Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes

BACKGROUND. Mutational inactivation in cancer of key apoptotic pathway components, such as TP53/p53, undermines cytotoxic therapies that aim to increase apoptosis. Accordingly, TP53 mutations are reproducibly associated with poor treatment outcomes. Moreover, cytotoxic treatments destroy normal stem...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Saunthararajah, Yogen, Sekeres, Mikkael, Advani, Anjali, Mahfouz, Reda, Durkin, Lisa, Radivoyevitch, Tomas, Englehaupt, Ricki, Juersivich, Joy, Cooper, Kathleen, Husseinzadeh, Holleh, Przychodzen, Bartlomiej, Rump, Matthew, Hobson, Sean, Earl, Marc, Sobecks, Ronald, Dean, Robert, Reu, Frederic, Tiu, Ramon, Hamilton, Betty, Copelan, Edward, Lichtin, Alan, Hsi, Eric, Kalaycio, Matt, Maciejewski, Jaroslaw
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2015
Matèries:
Clinical Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4362268/
https://ncbi.nlm.nih.gov/pubmed/25621498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78789
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars